Kaiser Health News
Survey: Americans Want Weight Loss Drugs Despite High Cost
by Julie Appleby, KFF Health News
Fri, 04 Aug 2023 09:00:00 +0000
Many Americans really want to lose weight — and a new poll shows nearly half of adults would be interested in taking a prescription drug to help them do so.
At the same time, enthusiasm dims sharply if the treatment comes as an injection, if it is not covered by insurance, or if the weight is likely to return after discontinuing treatment, a new nationwide KFF poll found.
Those findings display the enthusiasm for a new generation of pricey weight loss drugs hitting the market and illustrate possible stumbling blocks, as users potentially must deal with weekly self-injections, lack of insurance coverage, and the need to continue the medications indefinitely.
For example, interest dropped to 14% when respondents were asked if they would still consider taking prescription medications if they knew they could regain weight after stopping the drugs.
One way to interpret that finding is “people want to lose a few pounds but don’t want to be on a drug for the rest of their life,” said Ashley Kirzinger, KFF’s director of survey methodology. The monthly poll reached out to 1,327 U.S. adults.
The U.S. represents a large market for drugmakers who want to sell weight loss prescriptions: An estimated 42% of the population is classified as obese, according to a controversial metric known as BMI, or body mass index. In the KFF poll, 61% said they were currently trying to lose weight, although only 4% were taking a prescription medication to do so.
That gap between the 4% taking any kind of prescription weight loss treatment and the number of Americans deemed overweight or obese is the sweet spot drugmakers are targeting for the new drugs, which include several diabetes treatments repurposed as weight loss drugs.
The drugs have attracted much attention, both in mainstream publications and broadcasts and on social media, where they are often touted by celebrities and other influencers. Demand jumped and supplies have become limited. About 7 in 10 adults had heard at least “a little” about the new drugs, according to the survey.
The newer treatments include Wegovy, a slightly higher dose of Novo Nordisk’s diabetes drug Ozempic, and Mounjaro, an Eli Lilly diabetes treatment for which the company is currently seeking FDA approval as a weight loss drug.
Weight loss with these injectable drugs surpasses those of earlier generations of weight loss medications. But they are also costlier than previous drugs. The monthly costs of the drugs set by the drugmakers can range from $900 to more than $1,300.
At, say, a wholesale price tag of $1,350, the tab per person could top $323,000 over 20 years.
The drugs appear to work by mimicking a hormone that helps decrease appetite.
Still, like all drugs, they come with side effects, which can include nausea, diarrhea, vomiting, and constipation. More serious side effects include the risk of a type of thyroid cancer, inflammation of the pancreas, or low blood sugar. Health officials in Europe are investigating reports that the drugs may result in other side effects like suicidal thoughts.
The KFF survey found that 80% of adults thought insurers should cover the new weight loss drugs for those diagnosed as overweight or obese. Just over half wanted it covered for anyone who wanted to take it. Half would still support insurance coverage even if doing so could increase everyone’s monthly premiums. Still, 16% of those surveyed said they would be interested in a weight loss prescription even if their insurance did not cover it.
In practice, coverage for the new treatments varies, and private insurers often peg coverage to patients’ BMI, a ratio of height to weight. Medicare specifically bars coverage for drugs for “anorexia, weight loss, or weight gain,” although it pays for bariatric surgery.
“Unfortunately, a lot of insurers have not caught up to the idea of recognizing obesity as a disease,” said Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School.
Employers and insurers must consider the potential costs of covering the drugs for enrollees — perhaps for them to use indefinitely — against the potential savings associated with losing weight, such as a lower chance of diabetes or joint problems.
Stanford said the drugs are not a miracle cure and do not work for everyone. But for those who benefit, “it can be significantly life-altering in a positive way,” she said.
It’s not surprising, she added, that the drugs may need to be taken long term, as “the idea that there is a quick fix” doesn’t reflect the complexity of obesity as a disease.
While the drugs currently on the market are injectables, some drugmakers are developing oral weight loss drugs, although it is unclear whether the prices will be the same or less than the injectable products.
Still, many experts predict that a lot of money will be spent on weight loss products in the coming years. In a recent report, Morgan Stanley analysts called obesity “the new hypertension” and predicted industry revenue from U.S. sales of obesity drugs could rise from a current $1.6 billion annually to $31.5 billion by 2030.
By: Julie Appleby, KFF Health News
Title: Survey: Americans Want Weight Loss Drugs Despite High Cost
Sourced From: kffhealthnews.org/news/article/kff-poll-obesity-drugs-demand-high-cost-ozempic-wegovy-mounjaro/
Published Date: Fri, 04 Aug 2023 09:00:00 +0000
Kaiser Health News
A Toddler Got a Nasal Swab Test but Left Before Seeing a Doctor. The Bill was $445.
SUMMARY: In December, 3-year-old Ryan Wettstein Nauman from Peoria, Illinois, experienced inconsolable crying, prompting her mother, Maggi, to take her to the emergency room. After waiting, Ryan stopped crying and they decided to leave without seeing a doctor. Months later, they received a $445 bill for a covid and flu test conducted during their brief ER visit, despite Ryan only being triaged. After insurance adjustments, they owed $298.15. The high hospital markup and insurance rules post-public health emergency raised concerns for Wettstein, leading her to reconsider future ER visits in favor of urgent care options for non-life-threatening issues.
The post A Toddler Got a Nasal Swab Test but Left Before Seeing a Doctor. The Bill was $445. appeared first on kffhealthnews.org
Kaiser Health News
Florida’s Deloitte-Run Computer System Cut Off New Moms Entitled to Medicaid
SUMMARY: In May, Mandi Rokx, a Florida mother, received a notice that she and her baby would be cut from Medicaid despite being eligible. Florida’s 2021 law promised 12 months of continuous coverage post-birth, but a computer glitch in the state’s eligibility system, run by Deloitte, led to wrongful cuts. This error, along with others during Florida’s Medicaid review process, has affected many new mothers. A class-action lawsuit highlights how these errors led to loss of coverage for eligible individuals. While Rokx regained coverage after legal intervention, the broader issues persist, impacting thousands across multiple states.
The post Florida’s Deloitte-Run Computer System Cut Off New Moms Entitled to Medicaid appeared first on kffhealthnews.org
Kaiser Health News
Indiana Hospitals Pull Merger Application After Pushback Over Monopoly Concerns
SUMMARY: Two rival hospitals in Terre Haute, Indiana, withdrew their merger application just before a state ruling amidst public backlash against hospital monopolies. The proposed merger of Union Health and Terre Haute Regional Hospital, the only acute care providers in the area, would have created a single hospital operator for 58,000 residents. Although federal laws block monopolies, the hospitals sought approval under a state “Certificate of Public Advantage” (COPA) law. Concerns raised included reduced access, higher prices, and fewer choices. Union Health intends to resubmit a revised application by a July 2026 deadline after addressing regulators’ feedback.
The post Indiana Hospitals Pull Merger Application After Pushback Over Monopoly Concerns appeared first on kffhealthnews.org
-
Local News5 days ago
Introducing our Student Athlete of the Week: Ocean Springs’ very own Mackenzie Smith
-
News from the South - Georgia News Feed7 days ago
Jose Ibarra found guilty in murder of Laken Riley | FOX 5 News
-
News from the South - Kentucky News Feed7 days ago
Nicholasville organization activates weather plan in response to bitter cold temperatures
-
News from the South - Alabama News Feed6 days ago
Judge grants mistrial in Sheila Agee trial due to ‘unhinged juror’
-
News from the South - Florida News Feed5 days ago
Families still trying to recover after hurricanes as holidays near
-
News from the South - Alabama News Feed4 days ago
Alabama Impact: Saturday morning will start near-freezing, but some warmer weather returns in Ala…
-
The Conversation2 days ago
Opioid-free surgery treats pain at every physical and emotional level
-
News from the South - Georgia News Feed2 days ago
Closing arguments begin in Georgia’s longest-running trial